

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2019/040105 A3

(43) International Publication Date
28 February 2019 (28.02.2019)

(51) International Patent Classification:

C07D 451/06 (2006.01) C07D 211/44 (2006.01)
C07D 487/04 (2006.01) A61K 31/437 (2006.01)
C07D 487/08 (2006.01) A61K 31/438 (2006.01)
C07D 211/14 (2006.01) A61K 31/445 (2006.01)
C07D 211/58 (2006.01) A61K 31/4468 (2006.01)
C07D 413/04 (2006.01) A61K 31/46 (2006.01)
C07D 241/04 (2006.01) A61K 31/496 (2006.01)
C07D 207/08 (2006.01)

(21) International Application Number:

PCT/US2018/000352

(22) International Filing Date:

20 August 2018 (20.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/548,320 21 August 2017 (21.08.2017) US

(71) Applicant: **ACADIA PHARMACEUTICALS INC.**
[US/US]; 3611 Valley Centre Drive, Suite 300, San Diego,
CA 92130 (US).

(72) Inventors: **BURSTEIN, Ethan, S.**; 4168 Sturgeon
Court, San Diego, CA 92130 (US). **OLSSON, Roger**;
Klagshamnsvägen 99 A, SE-218 38 Bunkeflostrand (SE).
JANSSON, Karl, Erik; Spannmålsvägen 11, SE-247 55
Dalby (SE). **BERGNER, Magnus, Gustav, Wilhelm**; Fyn-
dvägen 18, SE-224 80 Lund (SE). **SKÖLD, Niklas, Patrik**;
Grisslevägen 3, SE-227 32 Lund (SE). **VON WACHEN-
FELDT, Henrik**; Hässleholmsgatan 2b, SE-214 43 Malmö
(SE). **POPOV, Kyrylo**; Kattfotsgränden 14, SE-247 56
Dalby (SE). **KOVALENKO, Oleksandr**; Jaktstigen 2,
Lgh. 1103, SE-226 52 Lund (SE). **KLINGSTEDT, Per,
Tomas**; Rudeboksvägen 341, SE-226 55 Lund (SE).
BORGSTRÖM, Björn, Gustav; Uardavägen 52 B, Lgh
1101, SE-224 71 Lund (SE). **WAHLSTRÖM, Larisa, Yu-
dina**; Västerlånggatan 50B, SE-241 31 Eslöv (SE).

(74) Agent: **RICH, Roger, C.** et al.; Jones Day, 250 Vesey
Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

18 April 2019 (18.04.2019)

(54) Title: COMPOUNDS, SALTS THEREOF AND THEIR USE IN THE TREATMENT OF DISEASES

(57) Abstract: The present disclosure relates to compounds according to Formula (I), treating diseases.

WO 2019/040105 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2018/000352

A. CLASSIFICATION OF SUBJECT MATTER					
INV.	C07D451/06	C07D487/04	C07D487/08	C07D211/14	C07D211/58
	C07D413/04	C07D241/04	C07D207/08	C07D211/44	A61K31/437
	A61K31/438	A61K31/445	A61K31/4468	A61K31/46	A61K31/496

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2017/018804 A1 (CHONG KUN DANG PHARMACEUTICAL CORP [KR]) 2 February 2017 (2017-02-02) table at pages 9-14 -----	1-4,6, 8-18,20, 23-30, 33-38, 40,41
X	WO 2013/110134 A1 (SPINIFEX PHARM PTY LTD [AU]; MCCARTHY THOMAS DAVID [AU]; NAYLOR ALAN []) 1 August 2013 (2013-08-01) pages 1-2; examples ----- -/--	1-4,6,8, 10,11, 13, 17-19, 24, 27-30, 33-37, 40,41

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 15 January 2019	Date of mailing of the international search report 22/03/2019
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Beyss-Kahana, Ellen

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2018/000352

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2013/110135 A1 (SPINIFEX PHARM PTY LTD [AU]; MCCARTHY THOMAS DAVID [AU]; NAYLOR ALAN []) 1 August 2013 (2013-08-01)</p> <p>pages 1-2; examples</p> <p>-----</p>	<p>1-4,6, 10,11, 13,17, 18, 24-30, 33-37, 40,41</p>
X	<p>RADHA CHARAN DASH, SHARAD H. BHOSALE*, SUHAS M. SHELKE, MUGDHA R. SURYAWANSHI AND KAKASAHEBR. MAHADIK: "Design, Synthesis, Pharmacological Evaluation and Descriptor Based Similarities Study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1-yl]acetamides as Potential Antipsychotics", MEDICINAL CHEMISTRY, vol. 8, 14 May 2012 (2012-05-14), pages 1069-1075, XP002787934, page 1071</p> <p>-----</p>	<p>1-4,6, 10,11, 13, 17-19, 24, 27-31, 33-37,41</p>
X	<p>LEPAILLEUR, A. ET AL.: "Dual Histamine H3R/Serotonin 5-HT4R Ligands with Antiamnesic Properties: Pharmacophore-Based Virtual Screening and Polypharmacology", JOURNAL OF CHEMICAL INFORMATION AND MODELLING, vol. 54, 23 May 2014 (2014-05-23), pages 1774-1784, XP002787935, DOI: 10.1021/ci500157n page 1778, cluster 25; abstract</p> <p>-----</p>	<p>1</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2018/000352

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-4, 6, 8-41(all partially)
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
6(completely); 1-4, 8-41(partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 6(completely); 1-4, 8-41(partially)

Compound of formula (I) wherein B means N or CH and A means a bond

2. claims: 5(completely); 1-4, 8-41(partially)

Compound of formula (I) wherein B means N or CH and A means C, S, O, NH

3. claims: 1-4, 7-41(all partially)

Compound of formula (I) wherein B means N or CH and A means C-O

4. claims: 1-4, 7-41(all partially)

Compound of formula (I) wherein B means NCH₂, CHNH

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-4, 6, 8-41(all partially)

Moreover the present claims 1-4, 6, 8-41 of invention 1 relates to an extremely large number of possible compounds, pharmaceutical compositions and uses thereof, due to the fact that formula (I) of claim 1 accordingly contains so many options, variables and possible permutations. Support and disclosure within the meaning of Articles 5 and 6 PCT are to be found, however, for only a very small proportion of the compounds claimed, see especially the examples.

Non-compliance with the substantive provisions is such that a meaningful search of the whole claimed subject-matter of invention 1 could not be carried out.

The Search Division considers the subject-matter of claim 1, wherein Y means the moieties as disclosed in present claim 2, to represent a subject-matter on which a meaningful search could be performed since it represents a legitimated scope of protection in view of the examples and biological results put forward.

It is furthermore stressed that, the initial phase of the search of invention 1 revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of claim 1 according to invention 1 may be said to define subject-matter for which protection might legitimately be sought. For these reasons, a meaningful search of the whole claimed subject-matter of invention 1 could not be carried out. The extent of the search was consequently restricted to those claimed compounds, which appear to be supported and to a generalisation of its structural formula, namely compounds of formula (I) wherein: Y is selected from the moieties as disclosed in present claim 2.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guidelines C-IV, 7.2), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2018/000352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2017018804	A1	02-02-2017	AU 2016299485 A1	08-02-2018
			BR 112018001716 A2	06-11-2018
			CA 2993918 A1	02-02-2017
			CN 108026056 A	11-05-2018
			EP 3330259 A1	06-06-2018
			JP 2018521110 A	02-08-2018
			KR 20170013187 A	06-02-2017
			PH 12018500162 A1	30-07-2018
			US 2018215743 A1	02-08-2018
			WO 2017018804 A1	02-02-2017

WO 2013110134	A1	01-08-2013	AU 2013202973 B2	02-06-2016
			CA 2861231 A1	01-08-2013
			CN 104470903 A	25-03-2015
			EP 2807153 A1	03-12-2014
			HK 1201533 A1	04-09-2015
			JP 6258867 B2	10-01-2018
			JP 2015504900 A	16-02-2015
			JP 2018076297 A	17-05-2018
			NZ 627560 A	26-08-2016
			US 2015011565 A1	08-01-2015
			US 2016257656 A1	08-09-2016
			WO 2013110134 A1	01-08-2013

WO 2013110135	A1	01-08-2013	AU 2013202978 B2	19-05-2016
			CA 2861233 A1	01-08-2013
			CN 104470930 A	25-03-2015
			EP 2807171 A1	03-12-2014
			HK 1201531 A1	04-09-2015
			JP 6073926 B2	01-02-2017
			JP 2015504901 A	16-02-2015
			NZ 627558 A	29-07-2016
			US 2015218180 A1	06-08-2015
			WO 2013110135 A1	01-08-2013
			ZA 201405257 B	26-10-2016
